Condition

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype clinical trials and research

• 6Clinical trials
• 5Countries

Newest Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype clinical trials

All recruiting trials (6)

• TTFields with FET-PET–Guided SRS for Recurrent Glioblastoma

  This trial tests whether adding FET-PET-guided stereotactic radiosurgery to TTFields helps adults with recurrent IDH-wildtype glioblastoma live longer than TTFields alone.

  Recruiting Prof. Franciszek Lukaszczyk Memorial Oncology Center · Bydgoszcz · NCT07668869

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• ONCOhabitats for surgical and treatment planning in IDH‑wildtype glioblastoma

  This project will try ONCOhabitats MRI software to see if its tumor 'habitat' maps can predict outcomes and help adults with IDH‑wildtype glioblastoma who are having surgery.

  Recruiting at 5 sites Universitat Politècnica de València · Alicante and 4 other locations · NCT07111195

• Metabolic, transcriptomic, and proteomic profiling of relapsed glioblastoma

  This project will see if comparing genes, proteins, and metabolism in original versus relapsed tumors can reveal markers or targets for people with relapsed IDH‑wildtype glioblastoma who had repeat surgery at CHU de Bordeaux.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT06430424

• Combining eflornithine and temozolomide for newly diagnosed glioblastoma

  This study is testing a new combination of two medications, eflornithine and temozolomide, to find the best dose for people with newly diagnosed glioblastoma.

  Recruiting at 7 sites Phase 1 Orbus Therapeutics, Inc. · Birmingham, Alabama and 7 other locations · NCT05879367

• Combining Debio 0123 with Temozolomide for Glioblastoma Treatment

  This study is testing if a new drug called Debio 0123, when combined with the standard treatment temozolomide, can help adults with glioblastoma feel better and improve their outcomes.

  Recruiting at 16 sites Phase 1/2 Debiopharm International SA · Chicago, Illinois and 15 other locations · NCT05765812

Related topics

Quick answers

How many Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in United States (3 trials), Spain (2 trials), Poland (1 trial), Switzerland (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →